Worldwide Bronchiolitis Industry to 2030 – Featuring Immunotek, Sanofi and AstraZeneca Among Others –

Worldwide Bronchiolitis Industry to 2030 – Featuring Immunotek, Sanofi and AstraZeneca Among Others –

Worldwide Bronchiolitis Industry to 2030 – Featuring Immunotek, Sanofi and AstraZeneca Among Others –

DUBLIN–(BUSINESS WIRE)–The “Bronchiolitis – Market Insights, Epidemiology, and Market Forecast – 2030” report has been added to’s offering.

This report delivers an in-depth understanding of the Bronchiolitis, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, France, Italy, Spain and the United Kingdom), and Japan.

The Bronchiolitis market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Bronchiolitis symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Bronchiolitis symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities. It assesses the underlying potential of the market.

Bronchiolitis Drug Chapters

The drug chapter segment of the report encloses detailed analysis of Bronchiolitis marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Bronchiolitis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Management of bronchiolitis is mostly supportive, assisting hydration and hypoxemia until improvement. With increased respiratory rate and nasal secretions, oral feeding is challenged, and those with severe disease require assistance with feeding by enteral or parenteral means. The threshold for supporting hydration is typically when an infant’s intake is reduced to 50-75% of the usual volume. Support for dehydration can be provided in the form of encouraging frequent small aliquots of oral, nasogastric, or intravenous hydration without a single modality being superior to the others. Severe bronchiolitis may be associated with greater potential for hyponatremia, and management with hypotonic fluids may also be associated with less favorable outcomes.

Ribavirin, a synthetic guanosine analog, is the only antiviral medication studied for the treatment of bronchiolitis. Its use is not routinely recommended by current guidelines.

The absence of an effective treatment for bronchiolitis makes prevention the best choice to reduce the burden of the disease and its impact on social health. In recent years, immunoprophylaxis with palivizumab, a humanized monoclonal antibody capable of neutralizing RSV, has effectively reduced hospitalization rates relating to RSV infections.

Bronchiolitis Emerging Drugs

Inmunotek is developing MV130 (Bactek) for the treatment of Bronchiolitis. MV130, which contains heat-inactivated bacteria besides inducing specific T cell immunity against the bacteria included in preparation also shows an enhanced T cell response to unrelated flu antigen. It triggers TLR and NLR signalling pathways on DCs releasing trained immunity hallmarks.

Many new therapies for Bronchiolitis are in various phases of development which have novel targets and mechanisms of action.

Bronchiolitis Market Outlook

The Bronchiolitis market outlook of the report helps build the detailed comprehension of the historic, current and forecasted Bronchiolitis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.

This segment gives a thorough detail of Bronchiolitis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to view the market at first sight clearly.

Key Findings

This section includes a glimpse of the Bronchiolitis market in the United States. The total market size of Bronchiolitis was found to be USD 56.1 Million in 2020, which is further expected to increase by 2030.

Scope of the Report

  • The report covers the descriptive overview of Bronchiolitis, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the Bronchiolitis epidemiology and treatment in the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • Additionally, an all-inclusive account of both the current and emerging therapies for Bronchiolitis is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the Bronchiolitis market; historical and forecasted is included in the report, covering drug outreach in the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Bronchiolitis market

Report Highlights

  • In the coming years, the Bronchiolitis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world, which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Bronchiolitis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Bronchiolitis. The launch of emerging therapies will significantly impact the Bronchiolitis market.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Bronchiolitis.

Companies Mentioned

  • Inmunotek
  • Sanofi
  • AstraZeneca
  • Novavax
  • Merck
  • Regeneron

For more information about this report visit


Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900